1 Product identity
Ingredient risk
Contains a high-risk ingredient
Super Phosphozyme
BrandBiotics Research Corporation→Other Combinations Tablet or Pill 9 ingredients 1 high-risk 1 caution DSLD #22220Net contents: 90 Tablet(s)
Target: Adults and Children 4 years and above
DSLD entry: 2013-06-25
2 Ingredients (9)
IngredientGroupSafety
Orthophosphoric AcidPhosphoric acid—
RNARNA—
Stearic AcidStearic Acid—
Ingredient amounts require the full DSLD label. View full label at NIH DSLD →
⛔ High-risk ingredient — documented serious harm
Inositol — GDM prevention — 4 g/day from first trimester in high-risk women [2]
⚠️ Use with caution — restricted in some markets
Magnesium — Severe deficiency (<0.50 mmol/L) causes secondary hypocalcemia and hypokalemia that will not correct until magnesium is repleted first [1].
3 Safety cross-reference
Vitamin C — Generally Safe
⚠ GI distress at high doses
⚠ Kidney stones risk >1g/day
Calcium — Conditionally Safe
⚠ Cardiovascular risk debated >1,000 mg/day
⚠ Kidney stones
Phosphorus — Generally Safe
⚠ Excess impairs calcium absorption
Inositol — High risk
⚠ GI disturbance at high doses (>12 g)
⚠ May lower blood glucose
Magnesium — Use with Caution
⚠ Diarrhea (especially oxide)
⚠ Accumulates in renal impairment
4 Label claims
• All Other
5 Data source
DSLD ID22220
Full labelView at NIH DSLD →
SourceOffice of Dietary Supplements, NIH
Market statusOn market
Entry date2013-06-25
6 More from Biotics Research Corporation
View Biotics Research Corporation Safety Scorecard → 240 products
5-HTP7-Keto-ZymeA.D.P.Acetyl-L-CarnitineADB5-PlusADHS7 Cite this page
Vancouver
Pkhakadze G. Super Phosphozyme — product analysis [Internet]. Tbilisi: Public Health Institute of Georgia; 2026 [cited 2026 Jul 29]. Available from: https://supplement.ge/products/super-phosphozyme-22220/
CC BY 4.0. Product data from NIH DSLD; safety analysis by SupplementIndex.
GP
Analyzed by SupplementIndex
PHIG · Editor-in-Chief: Prof. Giorgi Pkhakadze, MD, MPH, PhD
Product data sourced from the NIH Dietary Supplement Label Database (DSLD). Safety cross-referencing by SupplementIndex. This analysis is for informational purposes only. For corrections: info@accreditation.ge.
Publisher: PHIG
Publisher: PHIG